RE: Cathal Friel - Yahoo Finance Video3 Feb 2021 18:21
Hi Sportstrader,
It looks like Codagenix are the major client which has got the new facility off the ground; and they might have an option on 2H capacity for their Phase 2 challenge trial.
Other Codagenix plus points he mentioned :
- backer of Codagenix is Jim Simons , Euclidean Capital, the founder of Renaissance Capital *;
- Merck and Novartis are keen to push Codagenix as a 'next generation' coronavirus vaccine, because they missed out on round 1...
From their website
*.."A viral gene design algorithm that is unlike any first-generation vaccine platforms
Codagenix developed a viral gene customization algorithm that is unlike any first-generation vaccine platforms. We do not use an attenuated backbone virus carrying an antigen, virus-like particles (VLPs), or mRNAs expressing a single antigen. Those iterations of vaccine platforms are just that, “platforms,” or physical entities of some kind to which you can attach only 1 or 2 target antigens.
Codagenix’s unique approach targets the Achilles heel of all viruses.
Every virus, whether it is influenza, zika, or the common cold, uses the host cell machinery (ribosome) to translate its genome and synthesize its proteins – how the genome is read by the ribosome is our algorithm’s point of attack/attenuation
. The Codagenix computer algorithm re-codes and “deoptimizes” the codon pair bias/codon bias of viral genes – putting the genes in a language that is read slowly by the host cell ribosome.
These deoptimized genes encode the same exact protein sequences as the wildtype but do so in a suboptimal fashion.
Deoptimization results in a vast reduction of pathogenesis, yet induction of a potent immune response given the presentation of all perfectly matched antigens of the wild type virus, yielding a potent vaccine.
Codagenix deoptimized viruses are ideal for use as live-attenuated vaccines and given the re-coding and atypical RNA, robust oncolytics for solid tumors.
HTH